TQC 3927
Alternative Names: TQC-3927Latest Information Update: 24 May 2024
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic obstructive pulmonary disease
Most Recent Events
- 17 May 2024 Preclinical trials in Chronic obstructive pulmonary disease in China (unspecified route) before May 2024
- 17 May 2024 Chia Tai Tianqing Pharmaceutical Group plans a phase I trial in Chronic obstructive pulmonary disease (In volunteers) in China (Inhalation, Powder) in May 2024 (NCT06408285)